Kaleido patch pump
ViCentra
What it is
A colorful, semi-patch insulin pump used in Europe, notably as the pump partner for Diabeloop's automated insulin delivery systems. Since 10 July 2026 the DBLG2 system — Kaleido plus a Dexcom G7, with the algorithm running on the user's own Android phone — is open for prescription in Germany, giving Kaleido a route off the soon-to-be-retired Dexcom G6.
Editorial review: .
Most recent recorded citation date: 2026-07-10. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Reliability: Commercial device with Diabeloop ecosystem use, but independent large reliability datasets are limited.[5]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 76 × 20 + 58 × 20 + 74 × 20 + 75 × 15 + 45 × 10 + 52 × 15 = 6515; divide by total weight 100. Unrounded weighted result: 65.15.
The named pump partner for Diabeloop DBLG1 and now for the DBLG2 system with the Dexcom G7, live in Germany from July 2026. That matters because Kaleido on its own pairs with the Dexcom G6, which Dexcom plans to stop manufacturing after 1 July 2026 — DBLG2 is the G7 pathway.[2]
Commercial device with Diabeloop ecosystem use, but independent large reliability datasets are limited.[5]
Small on-body semi-patch design reduces tubing burden compared with conventional tubed pumps.[1]
With the DBLG2 launch (Germany, July 2026) the algorithm runs on the user's own Android smartphone, with no dedicated handset in the DBLG2 framing. An iOS version is stated as coming soon, so iPhone users are still waiting.[2]
Available in Germany, with the Netherlands to follow under the gradual European launch. DBLG2 prescriptions with the Dexcom G7 opened in Germany on 10 July 2026, with the Netherlands to follow. No US clearance is documented in the sources checked.[2]
The full picture
Kaleido is best understood as a pump-platform option inside Europe’s modular AID ecosystem. It does not dominate attention the way Omnipod does, but it is the delivery half of Diabeloop’s automated insulin delivery systems, and that partnership is what keeps it a live component of the next commercial AID wave.
What changed in July 2026
On 10 July 2026, Diabeloop and ViCentra announced that the DBLG2 system — the DBLG2 algorithm, a Dexcom G7 sensor and a Kaleido pump — is open for prescription in Germany.23 The Netherlands is expected to follow later in 2026; as of 27 August 2026 ViCentra's site still says the Dutch DBLG2 launch will follow later in 2026, and no live Netherlands go-live has been posted.1 This is a real German go-live, not just the CE mark that was announced back in May 2026.23
Two things about it matter to anyone actually wearing the system:
- The dedicated handset is gone from the DBLG2 framing. The DBLG2 algorithm now runs on the user’s own Android smartphone. Diabeloop states an iOS version is coming soon, so iPhone users are not yet served.3
- No mandatory meal announcements. Launch coverage describes DBLG2 as running without requiring the user to announce every meal — a meaningful reduction in daily admin, though it is not the same as a system that ignores food entirely.2
The move for existing DBLG1 users is described as a progressive transition rather than a hard cutover.3
Why the Dexcom G7 pathway is the real story
Be precise here, because the distinction is easy to blur: the Kaleido pump is not "G7-compatible" as a standalone device. G7 support arrives through the DBLG2 system. On its own, the current Kaleido pairs with the Dexcom G6 — and Dexcom plans to stop manufacturing the G6 after 1 July 2026.4
That made DBLG2 more than a feature upgrade. Without a G7 route, Kaleido users would eventually have been stranded on a sensor that was no longer being made. ViCentra said in April 2026 that it expected no immediate impact on Kaleido users from the G6 discontinuation; the July DBLG2 launch is what makes that reassurance concrete.4
Where it stands
Kaleido remains a European device — available in Germany, with the Netherlands to follow later in 2026 under a gradual wider European launch — with no US clearance documented in the sources checked. Independent, large-scale reliability data on the pump hardware itself is still thin compared with the long-running tubed and pod pumps it competes with. Judge it as a component of the Diabeloop loop, not as a pump you would pick in isolation.
What's next for this
- →Netherlands launch of DBLG2 with Kaleido and the Dexcom G7 · Still not announced as live as of 27 August 2026; manufacturer pages still say later in 2026 rather than a completed summer launch
- →iOS version of the DBLG2 app (Android only at launch) · Announced as coming soon
Sources
- [1]Kaleido insulin pump official site · Manufacturer
ViCentra. Kaleido insulin pump official site — live-checked 27 August 2026: DBLG2 currently available in Germany, Netherlands to follow later in 2026.
- [2]ViCentra Kaleido with G7, DBLG2 is now available, Diabeloop says · Science journalism · 2026-07-10 — DBLG2 open for prescription in Germany with Dexcom G7 and Kaleido; Netherlands to follow.
ViCentra Kaleido with G7, DBLG2 is now available, Diabeloop says — Drug Delivery Business, 10 July 2026.
- [3]Diabeloop announces CE marking and launch of DBLG2 with Dexcom G7 and Kaleido · Manufacturer · 2026-05-11
Diabeloop announces CE marking and gradual launch of the DBLG2 system with Dexcom G7 and ViCentra's Kaleido — Diabeloop, 11 May 2026.
- [4]ViCentra expects no immediate impact from Dexcom G6 discontinuation on Kaleido pump users · Science journalism · 2026-04-06
ViCentra expects no immediate impact from Dexcom G6 discontinuation on Kaleido pump users — Drug Delivery Business, 6 April 2026.
- [5]Diabeloop DBLG1 pump partners include Kaleido · Manufacturer · 2026-03-03